Radioactive-emission-measurement optimization to specific body structures
    11.
    发明授权
    Radioactive-emission-measurement optimization to specific body structures 有权
    放射性 - 排放测量优化到特定的身体结构

    公开(公告)号:US08094894B2

    公开(公告)日:2012-01-10

    申请号:US11607075

    申请日:2006-12-01

    Abstract: Systems, methods, and probes are provided for functional imaging by radioactive-emission-measurements, specific to body structures, such as the prostate, the esophagus, the cervix, the uterus, the ovaries, the heart, the breast, the brain, and the whole body, and other body structures. The nuclear imaging may be performed alone, or together with structural imaging, for example, by x-rays, ultrasound, or MRI. Preferably, the radioactive-emission-measuring probes include detectors, which are adapted for individual motions with respect to the probe housings, to generate views from different orientations and to change their view orientations. These motions are optimized with respect to functional information gained about the body structure, by identifying preferred sets of views for measurements, based on models of the body structures and information theoretic measures. A second iteration, for identifying preferred sets of views for measurements of a portion of a body structure, based on models of a location of a pathology that has been identified, makes it possible, in effect, to zoom in on a suspected pathology. The systems are preprogrammed to provide these motions automatically.

    Abstract translation: 提供了系统,方法和探针,用于通过放射性 - 发射测量,特异于身体结构,例如前列腺,食管,子宫颈,子宫,卵巢,心脏,乳房,大脑和 全身等身体结构。 核成像可以单独进行,或者与结构成像一起进行,例如通过X射线,超声或MRI进行。 优选地,放射性发射测量探针包括适于相对于探针外壳的单独运动的检测器,以从不同取向产生视图并改变其视图取向。 通过基于身体结构和信息理论测量的模型,通过识别用于测量的优选视图集合来优化关于身体结构获得的功能信息的这些运动。 基于已经识别的病理学位置的模型,用于识别体部结构的一部分的测量的优选视图组的第二迭代使得实际上可以放大可疑的病理学。 这些系统是预编程的,以自动提供这些运动。

    Protein activity modification
    13.
    发明申请
    Protein activity modification 有权
    蛋白活性修饰

    公开(公告)号:US20090292324A1

    公开(公告)日:2009-11-26

    申请号:US11792811

    申请日:2005-12-09

    CPC classification number: A61N1/32 A61N1/205 A61N1/326 C12N13/00

    Abstract: A method of modifying tissue behavior, including cardiac tissue, comprising: determining a desired modification of tissue behavior for at least one of treatment of a disease, short or long term modification of tissue behavior, assessing tissue state and assessing tissue response to stimulation; selecting an electric field having a known effect of modifying protein activation levels of at least one protein as an immediate response of a tissue to the field, said known effect correlated with said desired modification; and applying said field to said tissue.

    Abstract translation: 一种改变组织行为(包括心脏组织)的方法,包括:确定对疾病的治疗,组织行为的短期或长期改变,评估组织状态和评估组织对刺激的反应中的至少一种的组织行为的期望修饰; 选择具有将至少一种蛋白质的蛋白激活水平修饰为具有已知作用的电场作为组织对场的直接反应,所述已知作用与所述期望的修饰相关; 并将所述场应用于所述组织。

    Gastrointestinal methods and apparatus for use in treating disorders
    20.
    发明申请
    Gastrointestinal methods and apparatus for use in treating disorders 有权
    用于治疗疾病的胃肠道方法和装置

    公开(公告)号:US20070179556A1

    公开(公告)日:2007-08-02

    申请号:US10561491

    申请日:2004-06-20

    Abstract: A method is provided for detecting a change in posture of a subject. An electrical impedance is measured between two or more sites on a stomach (20) of the subject, and an impedance signal is generated responsive thereto. The change in posture is detected by performing a posture analysis of the impedance signal. A method is also provided for treating a subject. The method includes applying an electrical signal to a site of the subject selected from the list consisting of: a colon (402) of the subject, and a distal small intestine (408) of the subject. The signal is configured to stimulate cells of the subject to increase secretion of glucagon-like-peptide-1 (GLP-1) or PYY, or to decrease secretion of ghrelin, in order to treat the subject.

    Abstract translation: 提供一种用于检测被检体的姿势变化的方法。 在受试者的胃(20)上的两个或更多个部位之间测量电阻抗,并且响应于此产生阻抗信号。 通过进行阻抗信号的姿势分析来检测姿势的变化。 还提供了一种治疗受试者的方法。 该方法包括将电信号施加到从包括受试者的结肠(402)和受试者的远端小肠(408)的列表中选择的对象的部位。 信号被配置为刺激受试者的细胞以增加胰高血糖素样肽-1(GLP-1)或PYY的分泌,或者降低生长素释放肽的分泌,以便治疗受试者。

Patent Agency Ranking